hepatocellular carcinoma
Conditions
Interventions
TACE with miriplatin
TACE with DC bead
Sponsors
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Clinically diagnosed as hepatocellular carcinoma patient. 2)Unresectable hepatocellular carcinoma. 3)20 years of age or older. 4)ECOG performance status 0 or 1. 5)Having measurable lesion in the liver. 6)TMN stage 2 or 3 7)Having indication for TACE. 8)Total birilubin<3.0mg/dl, AST and ALT equal to or less than five times the upper limit. 9)Elapsed 4 weeks or more after previous treatment. 10)Obtained written consent from the patient. 11)Child-Pugh score A or B. 12)Possible to perform the study procedure. 13)Obtained written consent from the patient before study.
Exclusion criteria
Exclusion criteria: 1)Having metastasis. 2)Having vascular invasion. 3)Having vascular anormality or AP shunt. 4)Having previous treatment with miriplatin or DC bead. 5)Having previous treatment with sorafenib. 6)Having severe ascites or pleural effusion. 7)Considered as HCC refractory for TACE. 8)Having allergy of contrast agent. 9)Having severe renal failure. 10)Having severe cardiac disease. 11)Having other cancer. 12)Having hemorrhagic varix. 13)Having severe mental disorder. 14)Having severe drug allergy. 15)Having possibility of pregnant or nursing. 16)Deemed inappropriate to perform the study by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-tumor response | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Countries
Japan
Contacts
Public ContactYoji Ishizu
Nagoya University Graduate School of Medicine, Aichi, Japan Department of Gastroenterology and Hepatology
Outcome results
None listed